Payment overview · 2025
General Payments
$1,269.48
37 reported records · 20 companies
Healthcare provider profile · identity verified
Robert Polofsky
Allopathic & Osteopathic Physicians|Family Medicine · AMITYVILLE, NY · NPI 1902830557
Verified facts
What the public records show
CMS Open Payments records show Robert Polofsky received $1,269.48 in general payments during 2025 across 37 reported records.
Xeris Pharmaceuticals, Inc. accounted for 13.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $173.49 | 13.7% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $160.22 | 12.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $135.45 | 10.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $108.80 | 8.6% | 4 | 2025 |
| Sekisui Diagnostics LLC | Unresolved — no canonical attribution shown | $100.00 | 7.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $91.66 | 7.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.34 | 5.7% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $59.61 | 4.7% | 2 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $46.82 | 3.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.43 | 3.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.06 | 3.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.64 | 2.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.09 | 2.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.64 | 2.3% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $28.42 | 2.2% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $28.29 | 2.2% | 1 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $26.18 | 2.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $23.81 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.89 | 1.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.64 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,169.48 | 36 |
| Gift | $100.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $160.22 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $135.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $118.80 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $108.80 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $91.66 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $91.66 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $60.73 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $59.61 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $54.08 | 2 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $46.82 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.43 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $41.06 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $41.06 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $41.06 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.64 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $28.42 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $28.29 | 1 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $26.18 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 100 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 246 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
246 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 355 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 354 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 326 | 102 |
| Losartan Potassium | Losartan Potassium | 294 | 80 |
| Montelukast Sodium | Montelukast Sodium | 292 | 123 |
| Ozempic | Semaglutide | 246 | 42 |
| Metformin Hcl Er | Metformin Hcl | 216 | 65 |
| Famotidine | Famotidine | 207 | 67 |
| Ezetimibe | Ezetimibe | 190 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 180 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 173 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 49 |
| Omeprazole | Omeprazole | 146 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 43 |
| Simvastatin | Simvastatin | 129 | 35 |
| Alprazolam | Alprazolam | 121 | 36 |
| Pregabalin | Pregabalin | 102 | 28 |
| Farxiga | Dapagliflozin Propanediol | 100 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 40 |
| Lisinopril | Lisinopril | 95 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 25 |
| Jardiance | Empagliflozin | 90 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 88 | 61 |
| Gabapentin | Gabapentin | 87 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 40 |
| Donepezil Hcl | Donepezil Hcl | 76 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 76 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 75 | 14 |
| Methylprednisolone | Methylprednisolone | 73 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 22 |
| Furosemide | Furosemide | 67 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 12 |
| Carvedilol | Carvedilol | 56 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 16 |
| Azithromycin | Azithromycin | 55 | 47 |
| Meloxicam | Meloxicam | 55 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 14 |
| Metformin Hcl | Metformin Hcl | 53 | 18 |
| Mounjaro | Tirzepatide | 53 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | 11 |
| Tramadol Hcl | Tramadol Hcl | 50 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 34 |
| Mupirocin | Mupirocin | 45 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 36 |
| Eliquis | Apixaban | 41 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 11 |
| Meclizine Hcl | Meclizine Hcl | 40 | 25 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 40 | suppressed |
| Allopurinol | Allopurinol | 38 | 13 |
| Alendronate Sodium | Alendronate Sodium | 35 | 12 |
| Diazepam | Diazepam | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | 11 |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 16 |
| Labetalol Hcl | Labetalol Hcl | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Celecoxib | Celecoxib | 30 | 19 |
| Potassium Chloride | Potassium Chloride | 30 | 11 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | 13 |
| Atenolol | Atenolol | 29 | 11 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 18 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | 11 |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | 12 |
| Colchicine | Colchicine | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Nystatin | Nystatin | 15 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Fluvastatin Sodium | Fluvastatin Sodium | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | 11 |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,269.48 · 37 records | Xeris Pharmaceuticals, Inc. | ABRYSVO, AIRSUPRA, Auvelity, COMIRNATY, Cologuard Collection Kit, FARXIGA, GVOKE HYPOPEN, IBSRELA, ISTURISA, KEVEYIS, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, LEQVIO, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, RECORLEV, REPATHA, REXULTI, Rybelsus, TELEPATCH CARDIAC MONITOR, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error